Myasthenia gravis is not a form of muscular dystrophy. Although both conditions cause muscle weakness, they are fundamentally different diseases with different causes, different mechanisms, and different treatments. Myasthenia gravis is an autoimmune disease that disrupts the signal between nerves and muscles. Muscular dystrophy is a group of inherited genetic disorders in which the muscle fibers themselves break down over time.
Where the Problem Occurs
The confusion between these two conditions makes sense on the surface: both involve muscles that don’t work the way they should. But the site of the problem is completely different.
In myasthenia gravis, the muscles themselves are structurally normal. The problem occurs at the neuromuscular junction, the tiny gap where a nerve cell communicates with a muscle fiber. Normally, nerves release a chemical messenger that binds to receptors on the muscle, telling it to contract. In myasthenia gravis, the immune system produces antibodies that block, destroy, or force the removal of those receptors. A single antibody can even disrupt this process through multiple pathways at once. The result is that nerve signals don’t reach the muscle effectively, and the muscle can’t contract with full strength.
In muscular dystrophy, the nerve signal arrives at the muscle just fine. The problem is inside the muscle fiber itself. Muscular dystrophies involve mutations in more than 40 different genes that produce proteins essential for holding muscle cells together. In Duchenne muscular dystrophy, the most common form, the gene responsible for producing a protein called dystrophin is mutated. Dystrophin acts like an anchor, connecting the internal machinery of a muscle fiber to the supportive structure surrounding it. Without it, muscle cell membranes become fragile and susceptible to damage every time the muscle contracts. Over time, healthy muscle fibers are lost and replaced by scar tissue and fat, progressively reducing the muscle’s ability to generate force.
How the Weakness Feels Different
One of the clearest differences between these conditions is the pattern of weakness throughout the day. Myasthenia gravis causes a distinctive “fatigable” weakness: muscles work reasonably well after rest but get noticeably weaker with repeated use. Most people feel strongest in the morning and weakest by evening. The intensity can change from day to day, and symptoms often improve after a nap or a break.
Myasthenia gravis also tends to affect specific muscle groups early on. Drooping eyelids, double vision, difficulty swallowing, and changes in speech are common first symptoms. Limb weakness can develop but often comes later.
Muscular dystrophy, by contrast, causes a steady, progressive weakness that doesn’t fluctuate with rest or activity. A child with Duchenne muscular dystrophy, for example, gradually loses the ability to walk, typically by age 12. The weakness doesn’t come and go. It advances in one direction, worsening over months and years as more muscle tissue is replaced by non-functional tissue.
Who Gets Each Condition
The two diseases also strike very different populations. Muscular dystrophies are genetic, meaning they’re present from birth even if symptoms appear later. Duchenne muscular dystrophy affects roughly 1 in 3,500 to 5,000 newborn males worldwide, since the dystrophin gene sits on the X chromosome. Other forms of muscular dystrophy can appear in childhood or adulthood depending on the specific genetic mutation involved, but they all trace back to an inherited defect.
Myasthenia gravis is not inherited. It’s an autoimmune disease that can develop at any age, though it more commonly appears in younger women and older men. The immune system’s attack on the neuromuscular junction is thought to begin with a breakdown in self-tolerance, possibly originating in the thymus gland. Both immune cells and antibody-producing cells are involved in driving the disease.
How Each Condition Is Diagnosed
Because the underlying causes are so different, the diagnostic workups look nothing alike.
For myasthenia gravis, doctors primarily look for specific antibodies in the blood. The most common target is the acetylcholine receptor; antibodies against it are found in roughly 62 to 72 percent of confirmed MG patients, depending on the testing method used. A smaller subset of patients have antibodies targeting a different protein called MuSK. When blood tests are inconclusive, nerve stimulation studies can reveal the characteristic pattern of signals fading with repeated stimulation. Doctors may also test whether medications that temporarily boost nerve signaling improve the weakness.
For muscular dystrophy, the first clue is often a blood test showing elevated levels of creatine kinase, a protein that leaks out of damaged muscle cells. High levels suggest ongoing muscle breakdown. A definitive diagnosis comes from genetic testing, which identifies the specific mutation responsible. In Duchenne muscular dystrophy, the absence of detectable dystrophin protein confirms the diagnosis.
Treatment and Outlook
Treatment strategies reflect the fundamental difference between these diseases. In myasthenia gravis, the goal is to improve nerve-to-muscle signaling and calm the immune system’s attack. Medications that slow the breakdown of the chemical messenger at the neuromuscular junction can provide symptom relief. Immune-suppressing drugs reduce the production of harmful antibodies. For many patients, surgical removal of the thymus gland offers lasting benefit. A landmark randomized trial in the New England Journal of Medicine found that thymectomy combined with medication produced significantly better outcomes over three years than medication alone: lower symptom scores, roughly 40 percent less need for steroids, and fewer hospitalizations for flare-ups.
Treatment for muscular dystrophy has historically focused on slowing progression and managing complications, since the underlying genetic defect cannot be reversed with conventional drugs. Physical therapy, bracing, and cardiac monitoring are mainstays of care. In 2025, the FDA approved a gene therapy for Duchenne muscular dystrophy in ambulatory patients aged 4 and older with a confirmed gene mutation. This therapy delivers a shortened version of the dystrophin gene to muscle cells, representing a fundamentally different treatment approach: replacing the missing protein rather than modulating the immune system.
The long-term outlook also differs substantially. Myasthenia gravis is a chronic condition, but with modern treatment most people can manage their symptoms effectively and maintain a normal or near-normal lifespan. Severe complications like respiratory failure can occur during flare-ups, but these are treatable emergencies rather than inevitable outcomes. Muscular dystrophies, particularly Duchenne, follow a more relentless course. Progressive muscle loss eventually affects the heart and breathing muscles, and even with advances in care, Duchenne muscular dystrophy significantly shortens lifespan.
Why the Confusion Happens
Both conditions fall under the broad umbrella of “neuromuscular diseases,” which is why they sometimes get lumped together. They both cause weakness. They both involve skeletal muscles. And the word “myasthenia” literally means “muscle weakness,” which sounds a lot like what muscular dystrophy does. But the similarity stops at the symptom. One is the immune system attacking a communication relay. The other is a genetic blueprint error that destroys the muscle itself. They require completely different tests to diagnose, completely different treatments to manage, and have very different trajectories over a lifetime.